Dr Alison Reid is a Consultant Medical Oncologist at the Royal Marsden NHS Foundation Trust specialising in the treatment of prostate and germ cell cancers. She worked in early Phase clinical trials at the Royal Marsden before pursuing a PhD in castration-resistant prostate cancer (CRPC) at The Institute of Cancer Research under the mentorship of Professors Colin Cooper and Johann de Bono. During her PhD, she ran the Phase II study of abiraterone acetate in post-docetaxel patients and examined the role of PTEN loss as a potential mechanism of resistance to abiraterone acetate. Dr Reid generated first-author and co-authored papers from this work. Dr Reid continues her interest in the management of CRPC and serves as PI on therapeutic trials and trials concerning predictive biomarkers and quality of life for patients. She is a member of the EORTC genitourinary group and the NCRI teenage and young adult and germ cell tumours clinical studies group and is committed to testicular cancer research focusing on understanding the mechanisms of treatment resistance and survivorship endeavours.